Riskpilot← Back to searchSign inGet full accessEquigyn AB
ABActiveOrg 5567126742Kvarngränd 10 Lgh 1401General medical practice activities · NACE 8621Est. 20060 employees
Revenue 2025
SEK 0
EBITDA margin
—
-114% vs 2024
Equity ratio
98.9%
Financial strength
Net profit 2025
SEK 979K
+173% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -39K | -114% |
| Net profit | SEK 979K | +173% |
| Total assets | SEK 6,8M | +8% |
| Equity | SEK 6,7M | +13% |
| Employees | 0 | — |
Legal name
Equigyn AB
Org number
5567126742
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
11 oktober 2006
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva sjukvårdsverksamhet, uthyrning av stallplatser, uppfödning av hästar, inackordering och träning av hästar, förvaltning av fast och lös egendom jämte därmed förenlig verksamhet.
Address
Kvarngränd 10 Lgh 1401
Phone
+4646189815
Email
peter_ottenstahl@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −33 | −18 | −18 | −18 | −39 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −33 | −18 | −18 | −18 | −39 |
| Net financials | 364 | — | 200 | 282 | 775 |
| Profit before tax | 357 | 137 | 337 | 384 | 1 036 |
| Tax | −0 | −31 | −33 | −25 | −56 |
| Net profit | 357 | 106 | 304 | 359 | 979 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6 574 | 6 357 | 6 339 | 6 337 | 6 821 |
| Equity | 5 815 | 5 721 | 5 825 | 5 979 | 6 748 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 30 | 61 | 94 | 59 | 73 |
| Total debt | 30 | 61 | 94 | 59 | 73 |
EBITDA margin
-3902500.0%
This company
15.8%
Market median
-24699467% vs market
20212025
Equity ratio
98.9%
This company
38.2%
Market median
+159% vs market
20212025
Return on equity
14.5%
This company
18.4%
Market median
+21% vs market
20212025
Net profit margin
97937700.0%
This company
8.1%
Market median
+1209107307% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
HM Audit | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Equigyn AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hanna Maria Ryttberg | Audit | 0 companies |
| Alexandra Ingrid Michaela Ottenstål | Deputy Board Member | 0 companies |
| Hans Peter Ottenstål | Board of Directors | 0 companies |